Welcome to our dedicated page for Strata Skin Sciences news (Ticker: SSKN), a resource for investors and traders seeking the latest updates and insights on Strata Skin Sciences stock.
STRATA Skin Sciences, Inc. (NASDAQ: SSKN) is a medical technology company focused on in-office dermatologic devices, and its news flow reflects that specialization. Company announcements frequently highlight developments related to its core technologies: the XTRAC® excimer laser, VTRAC® lamp systems, and the TheraClearX® Acne Therapy System. These updates often cover new clinical evidence, regulatory milestones, reimbursement decisions, and commercial expansion in dermatology markets.
Investors and clinicians following SSKN news can expect regular coverage of peer-reviewed studies involving XTRAC in conditions such as psoriasis, vitiligo, atopic dermatitis, and mycosis fungoides, including combination regimens with topical drugs and JAK inhibitors. STRATA frequently reports on published data that it believes support the safety, efficacy, and personalized use of excimer laser therapy across a range of inflammatory and autoimmune skin diseases.
News items also address reimbursement and policy developments. STRATA has issued releases on CMS Medicare Physician Fee Schedule decisions related to CPT® codes 96920–96922, including continued coverage, payment levels, and recognition of future code descriptor expansions for excimer laser procedures. These updates are relevant for understanding how reimbursement may influence utilization of XTRAC in U.S. dermatology clinics.
Corporate and capital markets updates are another recurring theme. STRATA uses news releases to communicate quarterly financial results, non-GAAP performance metrics, registered direct offerings, and at-the-market equity programs. The company also reports on its legal and competitive positioning, including litigation milestones against competing device manufacturers and the recapture of dermatology clinics into its XTRAC partnership network.
International growth initiatives, such as COFEPRIS clearance for TheraClearX in Mexico and partnerships with commercialization firms like MINO Labs, appear in STRATA’s news as the company expands its device-based acne and phototherapy offerings beyond the United States. For users of this SSKN news page, the feed provides an ongoing view into STRATA’s clinical, regulatory, commercial, and financial developments in the dermatology device space.
STRATA Skin Sciences (NASDAQ:SSKN), a medical technology company focused on dermatologic treatments, has completed its previously announced registered direct offering. The company successfully issued 1,097,547 shares of common stock at $2.204 per share, raising gross proceeds of approximately $2.42 million.
The offering, which closed on September 4, 2025, was conducted through Ladenburg Thalmann & Co. Inc. as the exclusive placement agent. STRATA plans to utilize the net proceeds for working capital and general corporate purposes. The securities were offered under an effective S-3 shelf registration statement.
STRATA Skin Sciences (NASDAQ: SSKN) reports significant success with its Elevate 360 (E360) consulting services platform, which helps partner clinics optimize their XTRAC laser treatment operations. The program focuses on implementing best practices in marketing, reimbursement, and patient retention.
Since early 2025, 99 out of 844 clinics have adopted E360, achieving an average 7% year-over-year growth. A notable case study showed one partner's revenue contribution to STRATA increasing from $10,500 in H1 2024 to $61,800 in H1 2025, while expanding from 2 to 9 clinics after implementing E360.
The program helps clinics optimize patient referrals, insurance reimbursement, scheduling, and follow-up visits, particularly beneficial with recent reimbursement improvements for vitiligo and auto-immune skin conditions.
STRATA Skin Sciences (NASDAQ: SSKN), a medical technology company focused on dermatologic treatments, has announced a $2.42 million registered direct offering of common stock. The company will sell 1,097,547 shares at $2.204 per share, priced at-market under Nasdaq rules.
The offering, expected to close around September 4, 2025, is being conducted with institutional investors, with Ladenburg Thalmann & Co. Inc. serving as the exclusive placement agent. STRATA plans to use the proceeds for working capital and general corporate purposes. The offering is being made through a shelf registration statement previously declared effective by the SEC.
STRATA Skin Sciences (NASDAQ: SSKN), a medical technology company focused on dermatologic treatments, announces its participation in the H.C. Wainwright 27th Annual Global Investment Conference. CEO Dr. Dolev Rafaeli will deliver a corporate overview presentation at the event, which takes place September 8-10, 2025 at the Lotte New York Palace Hotel.
The presentation will be available on demand starting September 5, 2025 at 7:00 AM ET for registered conference participants. Investors can request one-on-one meetings through the conference registration portal.
STRATA Skin Sciences (NASDAQ: SSKN) has affirmed its strong patent portfolio position for combination therapies using its XTRAC excimer laser with JAK inhibitors, systemic and biologic drugs. The company holds three key patents that protect the combined use of their technology with various therapeutic agents for treating dermatologic conditions.
The company is working with CMS to implement expanded CPT codes that would cover all inflammatory and autoimmune skin conditions, potentially tripling their addressable market by January 2026. This expansion includes conditions like vitiligo, atopic dermatitis, and alopecia areata, beyond their current psoriasis treatment.
STRATA's patents specifically cover the combination of UVB light therapy with systemic drugs, JAK inhibitors, and biological drugs, positioning the company at the forefront of integrative dermatologic treatment. The company is also engaged in defensive litigation with LaserOptek, expecting significant damages and injunctive relief.
STRATA Skin Sciences (NASDAQ: SSKN) reported Q2 2025 financial results showing decreased revenue and wider losses. Revenue declined 9% to $7.7 million, with global recurring revenue down 4% to $5.1 million and equipment revenue falling 18% to $2.5 million.
The company reported a net loss of $2.5 million ($0.60 per share) compared to a $0.1 million loss ($0.03 per share) in Q2 2024. Gross profit margin decreased to 56%, with cash position at $6.0 million as of June 30, 2025.
Key developments include historic expansion of CPT codes for skin disease treatments, potentially tripling the covered patient population, and strategic device management with 21 removals and 19 new placements of XTRAC devices. The company achieved near operating cashflow breakeven when adjusting for certain expenses.
STRATA Skin Sciences (NASDAQ: SSKN) is actively working with CMS to accelerate access to expanded reimbursement for its XTRAC® excimer laser treatment ahead of the planned January 1, 2027 implementation. The American Medical Association's CPT Editorial Panel has approved updates to expand reimbursement eligibility to include all inflammatory and autoimmune skin conditions, potentially making treatments accessible by 2026.
This expansion could triple the addressable market to over 30 million patients. Two recent peer-reviewed studies validate the efficacy of combining 308-nm excimer-laser therapy with JAK inhibitors for vitiligo treatment, showing a 100% overall response rate and 96% pigment stability. Additionally, the company provided updates on its ongoing litigation against LaserOptek regarding false advertising claims.
STRATA Skin Sciences (NASDAQ: SSKN), a medical technology company focused on dermatologic treatments, has scheduled its Q2 2025 earnings release for August 13, 2025 after market close.
The company will host a conference call at 4:30 p.m. ET the same day, featuring management remarks and a Q&A session. Investors can access the call via phone (U.S.: 1-866-524-3160, International: 1-412-317-6760) or through a live webcast. A replay will be available until August 20, 2025, using code 4200962.
FAQ
What is the current stock price of Strata Skin Sciences (SSKN)?
What is the market cap of Strata Skin Sciences (SSKN)?
